Cue Biopharma announces presentation of new CUE-101 data

Cue Biopharma (CUE) provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-100 series. Dimitrios Colevas presented new data from the company’s maturing Phase 1 trial evaluating CUE-101 in combination with Keytruda for patients with recurrent metastatic HPV+ head and neck squamous cell carcinoma. Data highlights include an overall response rate of 50% in patients with combined positive score greater than one and an ORR of 50% observed in patients with low CPS scores. This compares favorably to the historical ORR of 19% observed with pembrolizumab alone in the third-party KEYNOTE 048 trial. Notably, the 12-month overall survival of 88% in the Phase 1 trial represents a significant reduction in the risk of death compared to historical data from the KEYNOTE 048 study. The Kaplan-Meier estimate for median overall survival is currently 32 months.